Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3976 AL 3990

Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's β-amyloid self-assembly

Lee BI, Chung YJ, Park CB.

Biomaterials. 2019 Jan;190-191:121-132. doi: 10.1016/j.biomaterials.2018.10.043. Epub 2018 Oct 30.

Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Okuya M, Matsunaga S, Ikuta T, Kishi T, Iwata N.

J Alzheimers Dis. 2018;66(4):1379-1387. doi: 10.3233/JAD-180888.

Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease

Pradeepkiran JA, Reddy AP, Reddy PH.

Drug Discov Today. 2019 Feb;24(2):616-623. doi: 10.1016/j.drudis.2018.11.005. Epub 2018 Nov 16.

Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects

Kozin SA, Barykin EP, Mitkevich VA, Makarov AA.

Biochemistry (Mosc). 2018 Sep;83(9):1057-1067. doi: 10.1134/S0006297918090079.

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease

Camins A, Ettcheto M, Busquets O, Manzine PR, Castro-Torres RD, Beas-Zarate C, Verdaguer E, Sureda FX, Bulló M, Olloquequi J, Auladell C, Folch J.

Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1.

Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines

Bartolini M, Marco-Contelles J.

Chem Rec. 2019 May;19(5):927-937. doi: 10.1002/tcr.201800155. Epub 2018 Nov 29.

New approaches for the treatment of Alzheimer's disease

Fish PV, Steadman D, Bayle ED, Whiting P.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):125-133. doi: 10.1016/j.bmcl.2018.11.034. Epub 2018 Nov 19.

Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1

Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, Sakai JT, Mendes PFS, Varela ELP, Monteiro MC.

Oxid Med Cell Longev. 2018 Oct 30;2018:8152373. doi: 10.1155/2018/8152373. eCollection 2018.

Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease

Wang H, Zhang H.

ACS Chem Neurosci. 2019 Feb 20;10(2):852-862. doi: 10.1021/acschemneuro.8b00391. Epub 2018 Dec 6.

Translating the biology of aging into novel therapeutics for Alzheimer disease

Hara Y, McKeehan N, Fillit HM.

Neurology. 2019 Jan 8;92(2):84-93. doi: 10.1212/WNL.0000000000006745. Epub 2018 Dec 7.

Structure-Based Survey of the Binding Modes of BACE1 Inhibitors

Hu H, Chen Z, Xu X, Xu Y.

ACS Chem Neurosci. 2019 Feb 20;10(2):880-889. doi: 10.1021/acschemneuro.8b00420. Epub 2018 Dec 27.

Advances in developing novel therapeutic strategies for Alzheimer's disease

Cao J, Hou J, Ping J, Cai D.

Mol Neurodegener. 2018 Dec 12;13(1):64. doi: 10.1186/s13024-018-0299-8.

Neuroprotective and Neurological/Cognitive Enhancement Effects of Curcumin after Brain Ischemia Injury with Alzheimer's Disease Phenotype

Pluta R, Ułamek-Kozioł M, Czuczwar SJ.

Int J Mol Sci. 2018 Dec 12;19(12):4002. doi: 10.3390/ijms19124002.

Alzheimer's disease: understanding homeostasis deregulation to foster development of effective therapies

Nisticò R, Peineau S.

Pharmacol Res. 2019 Jan;139:467-468. doi: 10.1016/j.phrs.2018.12.011. Epub 2018 Dec 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias